← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Acurastem, Inc.
Pasadena, CA
$12,099,214
Total funding
5
Grants
Funding over time
peak $2.9M · FY2017–24$5M$3.8M$2.5M$1.3M$0
'17
'18
'19
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$12,099,214 · 5
By mechanism
R44$11,874,279 · 4
R43$224,935 · 1
Investigators at Acurastem, Inc.
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Emerging Leaders
6–10 yrs in
Largest grants
Development of a SYF2 antisense oligonucleotide treatment for ALS and FTD$1,492,509
R44 · FY2023 · AG
Development of a PIKFYVE antisense oligonucleotide treatment for FTD$1,480,550
R44 · FY2022 · NS
Development of a SYF2 antisense oligonucleotide treatment for ALS and FTD$1,402,110
R44 · FY2024 · AG
Development of an UNC13A antisense oligonucleotide treatment for ALS and FTD$1,390,906
R44 · FY2023 · NS
PIKFYVE antagonism as a therapy for C9ORF72-ALS/FTD$1,316,216
R44 · FY2019 · NS
Development of an UNC13A antisense oligonucleotide treatment for ALS and FTD$1,279,990
R44 · FY2024 · NS
PIKFYVE antagonism as a therapy for C9ORF72-ALS/FTD$1,148,751
R44 · FY2020 · NS
Development of a PIKFYVE antisense oligonucleotide treatment for FTD$1,014,266
R44 · FY2021 · NS
PIKFYVE antagonism as a therapy for C9ORF72-ALS/FTD$533,459
R44 · FY2021 · NS
PIKFYVE antagonism as a therapy for C9ORF72-ALS/FTD$433,105
R44 · FY2018 · NS
PIKFYVE antagonism as a therapy for C9ORF72-ALS/FTD$265,079
R44 · FY2019 · NS
Preserving cellular aspects of aging in patient-specific models of ALS$224,935
R43 · FY2017 · AG
Development of a PIKFYVE antisense oligonucleotide treatment for FTD$76,492
R44 · FY2022 · NS
Development of a PIKFYVE Antisense Oligonucleotide Treatment for FTD$40,846
R44 · FY2022 · NS